FDA Approves Alkermes' Aristada Drug As Schizophrenia Treatment Alkermes announced that the FDA has approved its extended-release injectable for schizophrenia treatment. Aristada, poised to be launched immediately, will offer once-a-month and six-week dosing options. by Katrina Pascual